From genome to resistance prediction.
The models, pipeline, and platform capabilities behind every BactoAI prediction.
A modern architecture, purpose-built for genomic AI.
Built for clinical labs, researchers, and public health.
Machine learning models trained on curated bacterial genomes.
Accepts assembled genomes in FASTA format.
Under 10 minutes from an assembled genome. Sequencing and assembly come first.
Upload requires sign-in. Genome files are analysed by our prediction service in the United States and deleted afterwards.
Downloadable PDF reports for research decision support.
It runs in your web browser, so no local setup is needed.
REST API for LIMS integration is planned.
Most useful for isolates already sequenced, for example in surveillance.
Export raw predictions for downstream analysis.
On-premises deployment is planned.
Designed with Kenya's Data Protection Act, 2019 in mind.
Models are updated only after independent validation results are reported.
BactoAI is a genomic prediction engine and the diagnostic layer other AMR tools build on.
BactoAI is a research prototype that predicts antimicrobial resistance from an assembled bacterial genome. Sequencing and assembly come first. It supports phenotypic susceptibility testing and does not replace it. We are not a lab-logistics or sample-booking marketplace, and not a guideline-based prescribing chatbot. Those tools move samples or protocols faster; BactoAI generates the resistance data point they both depend on.
Phenotypic testing needs a further 16-20 hours of incubation after isolation.
These tools apply WHO or national decision trees to symptoms without organism-specific resistance evidence.
Under 10 minutes from an assembled genome. Sequencing and assembly come first; most useful for isolates already sequenced, for example in surveillance.
For Hospitals
- Earlier antibiotic decisions
- Improved antimicrobial stewardship
- Reduced treatment failure
For Researchers
- Resistance surveillance
- Genomic analytics
- Dataset exploration
For Public Health
- National AMR monitoring
- Evidence-driven policy
- Population surveillance
Frequently asked questions
BactoAI is a research prototype, not approved for clinical use. It supports phenotypic susceptibility testing and does not replace it.
